Abiopharma

🔍 HEWSON MARILLYN A (Director)

Company: JOHNSON & JOHNSON (JNJ)

Report Date: 2025-03-04

Detailed Transactions and Holdings:

• Acquired 75 shares of Deferred Share Units (Derivative)
  Date: 2025-03-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 14,306.45 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2
• Acquired 206 shares of Deferred Share Units (Derivative)
  Date: 2026-03-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 14,512.94 | transaction_form_type: 4 | Footnotes: F3, F3, F3, F2

Footnotes:

• F1: Represents the acquisition of Deferred Share Units (DSUs) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors (the "Plan") that were not previously reported. DSUs are to be settled in cash upon termination of the Reporting Person's Directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date.
• F2: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person.
• F3: Acquisition of DSUs for deferral of cash retainer under the Plan.